MedPath

Clinical Trial News

Novel Drug Combinations Show Promise in Lung Cancer Treatment

  • Researchers have identified new drug combinations that enhance immunotherapy effectiveness in lung cancer, particularly in tumors resistant to standard treatments.
  • A study shows that combining ATR inhibitors with topotecan improves outcomes for relapsed small cell lung cancer by activating the immune system.
  • Combining KRAS G12C and SHP2 inhibitors with immunotherapy significantly reduced tumor size and recurrence in mice with lung cancer.
  • Dual checkpoint inhibitors may benefit non-small cell lung cancer patients with STK11 and KEAP1 mutations, improving response rates and survival.

Spinogenix's SPG302 Enters Phase 2 Trial as Novel Schizophrenia Treatment

  • Spinogenix has initiated a Phase 2 clinical trial to evaluate SPG302, a novel synaptic regenerative therapy, for the treatment of schizophrenia.
  • SPG302 aims to restore glutamatergic synapses, addressing a key feature of schizophrenia pathogenesis linked to positive, negative, and cognitive symptoms.
  • The Phase 2 trial is a randomized, double-blind, placebo-controlled study assessing the efficacy, safety, and tolerability of once-daily oral SPG302 in adults.
  • SPG302 has already received FDA Orphan Drug Designation for ALS and is under evaluation for Alzheimer's disease, showcasing its potential in neurodegenerative conditions.

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

NCT06427668RecruitingPhase 2
Spinogenix
Posted 7/29/2024

Study of SPG302 in Adults With Schizophrenia

NCT06442462RecruitingPhase 2
Spinogenix
Posted 8/1/2024

Study of SPG302 in Healthy Volunteers and ALS Participants

NCT05882695CompletedPhase 1
Spinogenix
Posted 7/3/2023

Shield Therapeutics' Oral Iron Suspension Shows Promise in Pediatric Trial

  • Shield Therapeutics' FORTIS/ST10-01-305 trial met all primary endpoints, demonstrating a clinically relevant increase in hemoglobin (Hb) levels over 12 weeks in children with iron deficiency.
  • In children aged 2-17, the mean Hb increase was 1.25 g/dL, while infants showed an increase of 1.77 g/dL, compared to 1.15 g/dL in the ferrous sulphate group.
  • No patients in the ferric maltol group discontinued the study due to treatment-related adverse events, highlighting the safety and tolerability of the oral liquid suspension.
  • Shield Therapeutics plans to submit regulatory applications to the FDA and EMA in the first half of 2025 for a pediatric indication, with potential for a €1m milestone payment from Norgine.

FDA Considers Narrowing PD-1 Inhibitor Label for Gastric Cancer Based on PD-L1 Expression

  • The FDA is considering limiting the use of PD-1 inhibitors like Keytruda and Opdivo in gastric adenocarcinoma based on PD-L1 expression levels.
  • FDA reviewers suggest that patients with low PD-L1 expression may not benefit substantially from these therapies, potentially exposing them to unnecessary risks.
  • Merck and BMS argue for maintaining the current broad label, while BeiGene supports consistent labeling across PD-1 agents, especially for patients with PD-L1 levels of at least 5%.
  • An FDA advisory committee meeting will discuss these concerns and the potential need for biomarker-driven treatment eligibility.

Keytruda-Favezelimab Combo Fails to Improve Survival in Colorectal Cancer Trial

  • Merck's Keytruda combined with favezelimab did not significantly improve overall survival in metastatic colorectal cancer patients in the Phase III KEYFORM-007 trial.
  • The trial enrolled over 440 patients with microsatellite stable metastatic colorectal cancer who had previously undergone standard treatments and were PD-L1 positive.
  • Despite the setback, Merck plans to continue evaluating Keytruda-based combinations and novel candidates for colorectal cancer, according to Catherine Pietanza.
  • This failure highlights the difficulty in developing effective treatments for MSS colorectal cancer, following a similar discontinuation by Bristol Myers Squibb in December 2023.

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

NCT05064059CompletedPhase 3
Merck Sharp & Dohme LLC
Posted 11/10/2021

Golfers Against Cancer Funds CU Cancer Center Research on Pediatric CAR T-cell Therapy

  • Golfers Against Cancer Denver funds three CU Cancer Center research projects focused on enhancing CAR T-cell therapy for pediatric cancers.
  • Researchers will investigate novel approaches, including particle backpacks for targeted drug delivery and logic-gated CAR-T cells, to improve treatment efficacy.
  • Studies target resistance mechanisms in B-cell acute lymphoblastic leukemia and aim to translate findings into impactful therapies for children with aggressive cancers.
  • The grants provide crucial seed funding for high-risk research, enabling investigators to gather preliminary data needed for larger NIH and Department of Defense grants.

Daehan Nupharm Launches Enpiflu Premix, a Single-Dose Influenza Treatment

  • Daehan Nupharm has launched Enpiflu Premix, a premixed peramivir hydrate injection, offering a single-dose intravenous treatment for influenza A and B in adults and children.
  • Clinical trials across Korea, Japan, and Taiwan involving 1,091 adult patients demonstrated peramivir's effectiveness is comparable to oseltamivir in reducing symptom duration.
  • Enpiflu Premix's ready-to-use formulation enhances safety and efficiency by eliminating compounding, reducing preparation time, and minimizing contamination risks.
  • The peramivir market has grown significantly, reaching 36.1 billion won in 2023, driven by increased influenza cases since the COVID-19 pandemic.

Condoliase (SI-6603) Shows Promise in Phase 3 Trials for Lumbar Disc Herniation

  • SI-6603, an investigational treatment, significantly improved leg pain compared to sham in U.S. and placebo in Japan at Week 13 in Phase 3 trials.
  • The studies involved intradiscal injections of SI-6603 and demonstrated statistically significant changes from baseline in worst leg pain.
  • Common adverse events included spinal MRI abnormalities and back pain, with no treatment-related serious adverse events reported in the U.S. study.
  • These findings support SI-6603's potential as a therapeutic option for radicular leg pain associated with lumbar disc herniation.

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

NCT03607838CompletedPhase 3
Seikagaku Corporation
Posted 5/30/2018

FDA Approves Heron Therapeutics' Zynrelef Vial Access Needle for Postoperative Pain Management

  • The FDA has approved Heron Therapeutics' Prior Approval Supplement Application for the Zynrelef Vial Access Needle (VAN).
  • The VAN simplifies aseptic preparation and significantly reduces Zynrelef's withdrawal time to 20-45 seconds.
  • Expected to launch in Q4 2024, the VAN aims to enhance safe use, increase adoption, and improve the preparation process of Zynrelef.
  • Zynrelef is a dual-acting local anesthetic combining bupivacaine and meloxicam, designed to reduce postoperative pain for up to 72 hours.

DURECT's Larsucosterol Shows Promise in Alcohol-Associated Hepatitis Treatment

  • DURECT Corporation's larsucosterol demonstrates potential in treating alcohol-associated hepatitis (AH) by reducing mortality rates in U.S. patients.
  • A Phase 3 trial, agreed upon with the FDA, will assess larsucosterol's efficacy with a 90-day survival primary endpoint, aiming for topline data within two years.
  • Larsucosterol targets DNA methyltransferases, epigenetic enzymes linked to hypermethylation in AH, offering a novel approach to managing the condition.
  • Data from the AHFIRM Phase 2b trial supports the Phase 3 design, showing significant mortality reduction with larsucosterol in U.S. patients.

A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment

NCT04563026CompletedPhase 2
Durect
Posted 1/22/2021

Trending News

1

Torrent Pharma Advances $2.4 Billion Acquisition of JB Chemicals in Major Industry Consolidation Move

2 days ago
2

FDA Approves Gamifant as First Treatment for Macrophage Activation Syndrome in Still's Disease

3 days ago
3

AbbVie Acquires In Vivo CAR-T Developer Capstan Therapeutics for Up to $2.1 Billion

2 hours ago
4

Stalicla Secures CHF 2 Million Financing from Addex Therapeutics to Advance Precision Medicine for Autism and Neurodevelopmental Disorders

9 hours ago
5

Klotho Neurosciences Advances Gene Therapy Manufacturing for ALS Treatment

9 hours ago
6

Hikma Pharmaceuticals Commits $1 Billion to Expand US Generic Medicine Manufacturing Through 2030

2 days ago
7

China Approves ORPATHYS-TAGRISSO Combination for EGFR-Mutated Lung Cancer with MET Amplification

6 hours ago
8

Roche Announces Leadership Changes as Head of Pharma R&D Hans Clevers Retires

9 hours ago
9

argenx Advances ARGX-119 to Registrational Study for Ultra-Rare Congenital Myasthenic Syndromes

9 hours ago
10

ESTEVE Acquires Caprelsa Rights from Sanofi to Expand Rare Cancer Treatment Portfolio

9 hours ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy